NEWS
- Clinical Development of ADC Drugs Targeting TROP-2
- The Rise of the TROP2-Directed ADCs for Solid Tumors
- Antibody–Drug Conjugates Targeting MUC1
- Global Sales of ADCs in 2023 – UP to 10 Billion
- From ADCs to ABCs: A New Strategy for High-Capacity Targeted Drug Delivery
- siRNA Therapeutics: Current Status & Delivery System
- RNA Therapies Update: Donidalorsen FDA Approved, Others Show Promise
- Nucleic Acid Therapeutics: Approvals and Potential Blockbusters
- Advances in Antibody-Targeted Lipid Nanoparticles (Ab-LNPs) and Their Emerging Therapeutic Applications
- Antibody-Oligonucleotide Conjugates (AOCs): Recent Advances